Montelukast Accord

Montelukast, the active ingredient in Montelukast Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma and allergic rhinitis in adults and children. GNH USA supplies Montelukast Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast Accord acts on the leukotriene pathway to control chronic respiratory and allergic conditions.

- Asthma: reduces bronchoconstriction and airway inflammation, improving control of persistent asthma. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions.

Common Side Effects: - Headache - Abdominal pain - Cough - Sore throat - Nausea - Diarrhoea

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema or anaphylaxis - Neuropsychiatric events including depression, anxiety or suicidal thoughts - Elevated liver enzymes or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic pneumonia

When prescribing Montelukast Accord, consider the following safety points.

- Acute asthma attacks: do not use as rescue medication; provide a fast‑acting bronchodilator instead. - Neuropsychiatric events: monitor patients for mood changes, depression or suicidal ideation. - Hepatic impairment: use with caution; dose adjustment may be required. - Known hypersensitivity: avoid in patients with documented allergy to Montelukast or any component of the tablet. - Pregnancy and lactation: assess risk‑benefit, as limited data are available. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may reduce Montelukast plasma concentrations and efficacy. - Ketoconazole: strong CYP3A4 inhibition can increase Montelukast levels, raising risk of adverse effects. - Other leukotriene pathway inhibitors (e.g., zileuton): additive effect may increase risk of liver toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: possible alteration of hormonal effectiveness. - Theophylline: monitor plasma concentrations as Montelukast may affect metabolism.